← Back to Search

Dopamine Agonist

Lisuride for Cocaine Use Disorder

Phase 1

Waitlist Available

Led By Walter Ling, M.D.

Research Sponsored by National Institute on Drug Abuse (NIDA)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

M/F ages 21-50

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will study the effects of lisuride on cocaine dependence and safety in a group of crack users.

Who is the study for?

This trial is for men and women aged 21-50 who are dependent on cocaine as per DSM-IV criteria. Participants must consent to the study's terms. Those with psychiatric disorders needing medication, pregnant or nursing women, a history of seizures, acute hepatitis, or other unsafe medical conditions can't join.Check my eligibility

What is being tested?

The study aims to assess the safety of lisuride in individuals addicted to crack cocaine and its effects when combined with cocaine. It will explore how lisuride alters both the subjective experience and physical response to cocaine use.See study design

What are the potential side effects?

Potential side effects may include reactions specific to lisuride or its interaction with cocaine such as changes in blood pressure, mood alterations, nausea, headaches, dizziness or other physiological responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 21 and 50 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Characterization of study population

Clinical physiological response to cocaine challen

Degree of drug craving

+7 more

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)Lead Sponsor

2,468 Previous Clinical Trials

2,619,346 Total Patients Enrolled

Walter Ling, M.D.Principal InvestigatorFriends Research Institute, Inc.

38 Previous Clinical Trials

4,116 Total Patients Enrolled

Media Library

Lisuride (Dopamine Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT00000338 — Phase 1

Cocaine Use Disorder Research Study Groups:

Cocaine Use Disorder Clinical Trial 2023: Lisuride Highlights & Side Effects. Trial Name: NCT00000338 — Phase 1

Lisuride (Dopamine Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00000338 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I qualify to join this research endeavor?

"To be selected as a participant in this trial, applicants should have an established history of cocaine abuse and must be between the ages 21 and 50. Currently, up to two individuals will receive enrolment into the study."

Answered by AI

Has this treatment received regulatory endorsement?

"With minimal safety and efficacy data, this therapeutic intervention received a score of 1 in our risk assessment."

Answered by AI

Does the protocol for this trial extend to individuals over 55 years of age?

"Per the outlined enrollment criteria, an individual must be between 21 and 50 years old to qualify for this trial."

Answered by AI

Is this experiment recruiting new participants right now?

"Data found on clinicaltrials.gov reveals that, while this trial was initially posted in March 1996 and last changed January 2017, it is not currently enrolling participants. Nevertheless, there are 18 other medical studies actively searching for subjects right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Infusion Laboratory: Protocol 2 (Lisuride) - 3

1996. "Infusion Laboratory: Protocol 2 (Lisuride) - 3". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00000338.